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Abstract
Background: Recent reviews suggest common infectious diseases continue to be a major cause of death among preschool
children in developing countries. Identification of feasible strategies to combat this disease burden is an important public
health need. We evaluated the efficacy of adding prebiotic oligosaccharide and probiotic Bifidobacterium lactis HN019 to
milk, in preventing diarrhea, respiratory infections and severe illnesses, in children aged 1–4 years as part of a four group
study design, running two studies simultaneously.
Methods and Findings: In a community based double-masked, randomized controlled trial, children 1–3 years of age,
willing to participate, were randomly allocated to receive either control milk (Co; n=312) or the same milk fortified with
2.4 g/day of prebiotic oligosaccharide and 1.9610
7 colony forming unit (c.f.u)/day of probiotic Bifidobacterium lactis HN019
(PP; n=312). Children were followed up for 1 year providing data for 1–4 years. Biweekly household surveillance was
conducted to gather information on compliance and morbidity. Both study groups were comparable at baseline;
compliance to intervention was similar. Overall, there was no effect of prebiotic and probiotic on diarrhea (6% reduction,
95% Confidence Interval [CI]: 21 to 12%; p=0.08). Incidence of dysentery episodes was reduced by 21% (95% CI: 0 to 38%;
p=0.05). Incidence of pneumonia was reduced by 24% (95% CI: 0 to 42%; p=0.05) and severe acute lower respiratory
infection (ALRI) by 35% (95% CI: 0 to 58%; p=0.05). Compared to children in Co group, children in PP group had 16% (95%
CI: 5 to 26%, p=0.004) and 5% (95% CI: 0 to 10%; p=0.05) reduction in days with severe illness and high fever respectively.
Conclusions/Significance: Milk can be a good medium for delivery of prebiotic and probiotic and resulted in significant
reduction of dysentery, respiratory morbidity and febrile illness. Overall, impact of diarrhea was not significant. These
findings need confirmation in other settings.
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Introduction
Globally, 5.2 million children under five years of age die every
year due to preventable infectious diseases like pneumonia,
diarrhea, malaria and measles [1]. Recent findings suggest 21%
of global deaths and disability adjusted life years in children
younger than 5 years of age are attributable to under nutrition and
its synergistic relationship with preventable infectious diseases
[2,3]. Interventions are needed for prevention of these diseases for
achieving Millennium Development Goals for child survival and
reduction in child mortality by two-thirds by 2015 [4–6].
Probiotic bacteria benefit the host by adhering to the gut
epithelium, stimulating host immune response, inhibiting epithelial
and mucosal adherence of pathogens and producing antimicrobial
substances [7]. Non-digestible carbohydrates that favor the growth
and/or activity of probiotic bacteria are termed Prebiotics [8].
There has been increasing evidence in the last decade for efficacy
of probiotic agents in treatment of acute diarrhea [7,9–12],
persistent diarrhea [13] and prevention of antibiotic associated
diarrhea [14–16]. The evidence for impact on non-diarrheal
illnesses has been unclear [17–20]. The data on efficacy for
prevention of morbidity has been limited to small studies, mainly
hospital based with short follow up or day care center based, with
small sample size and short follow-ups [21–22]. Until date, only
three randomized controlled trials have reported role of probiotics
in prevention of community-acquired diarrhea [18,20,23]. Of
these, two were in day care centers [18,20] one of which was in
developed country [20]. Data on combined use of prebiotics and
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community setting from developing countries is lacking as are
data evaluating the effect on illness other than diarrhea.
We undertook a community-based, doubled-masked random-
ized trial with four arms to evaluate the effect of two different milk
interventions in comparison to their respective control groups
(essentially running two trials concurrently with a common
randomization). Two groups evaluated impact of fortifying a
regular milk with micronutrient bundle in comparison to same
milk without fortification; and the other two groups evaluated
fortification of a pre-fortified premium milk with prebiotic and
probiotic in comparison to same milk without prebiotic and
probiotic fortification. In this paper we are reporting the results of
the two arms evaluating efficacy of consumption of prebiotic
oligosaccharide and probiotic Bifidobacterium lactis HN019 fortified
milk for a period of one year, in preventing childhood morbidity
among children 1–4 years old in a peri-urban community based
setting in India. The results of the other two arms are reported
separately in a companion paper [24].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting; see Checklist S1 and Protocol S1.
Population Description and Eligibility
The trial was carried out between April 2002 and April 2004, at
Sangam Vihar, New Delhi, India. Detailed population description
has previously been reported [25]. Briefly most of the inhabitants
are migrants from eastern Uttar Pradesh, Bihar and Rajasthan.
Literacy rates are low with 50% of the women being illiterate.
About 80% men work as daily wage laborers or in factories, while
95% of women are housewives. Average family income is below
600 $/year. Community has minimal access to sewage, drinking
water and paved roads. Diarrhea and respiratory illnesses are
common causes of childhood mortality and morbidity. Breastfeed-
ing is a common universal practice in the first year of life, though it
starts declining after first year.
From a regularly updated database, all permanent resident
families in area with children 1–3 years were invited to participate
in the study and consent sought. Children with severe malnutrition
needing rehabilitation by protocol were to be excluded; however,
no such child was encountered. Children allergic to milk or with
history of lactose intolerance were not enrolled into the trial.
Ethics
The study protocol was approved by the human research and
ethical review committees at the Johns Hopkins University, USA
and the Annamalai University, India. The purpose of the study
was explained to the parents in the local language, and a written
informed consent was obtained. Procedure consisted of supervisor
visiting the household and in presence of a third party, obtaining
the consent from the mother or father after reading the consent
form to them. Parents were given a choice to sign the consent form
or if they were illiterate and/or could not sign, supervisor and the
witness signed to document the consent.
This procedure had been approved by both institutional review
boards’ as majority of the mothers cannot sign in this population
and taking thumb impression is stigmatized due to misuse during
colonial era.
Enrollment and baseline evaluation
Consented children were enrolled into the study and scheduled
for baseline assessments in the clinic. Detailed physician
examination of the child, blood sampling for assessment of body
iron stores and anaemia, and weight (SECA Corporation,
Columbia MD/ATCO Weighing Solutions Company Ltd, India)
and height/length (Shorr Productions, Olney, MD) measurements
were undertaken. Venous blood sample was collected by a trained
nurse in trace free syringes to avoid micronutrient contamination.
Blood samples were analyzed for a detailed hemogram using a
coulter automated flow cytometer (Beckman-Coulter, Fullerton,
CA), zinc protoporphyrin using hematoflourometer (AVIV
Biomedical, Lakewood, NJ), serum ferritin and serum transferrin
by commercial enzyme linked immunosorbant assay kits (Spectro
Ferritin Kit, Spectro Transferrin kit; Ramco Laboratories, Inc,
Houston, Texas). In our study, children with hemoglobin (Hb)
#100 g/L were considered anemic and classified as iron deficient
if they satisfied any two of the following four conditions: Serum
ferritin #12 mg/L, serum transferrin .8.3 mg/ml, hematocrit
#30%, zinc protoporphyrin $80 mmol per mole of heme.
Randomization and Masking
The study was a double blind randomized controlled trial with
four arms wherein we evaluated the effect of two separate
interventions in comparison to their respective controls. Four letter
codes namely A, B, C or D were identified for each treatment
group across the two trials. Permuted fixed block randomization
with block length of 16 was used.
Two separate randomization lists were generated using an in-
house computerized randomization schedule - Strata one for
baseline Hb.70 g/L and strata two for baseline Hb#70 g/L.
Based on their baseline Hb, children were stratified into these
strata and assigned a treatment code. The supplementation sachets
were identical in color, size (weight 32 g), taste, and were labeled
with letter code. In the field, the letter code of the supplementation
box was stripped off and labeled with child’s identification
information. The product corresponding with the letter code
was known only to the manufacturing supervisor at Fonterra
Brands (Singapore) Pte. Ltd. It was not known to investigators or
anyone in the field until study completion and analysis. Morbidity
impact of the micronutrient arm and its control has been
previously published [25].
Sample Size Estimation
The sample size was determined on the assumption that
prebiotic and probiotic intervention would decrease diarrhea
incidence by 15% and episodes of pneumonia by 25% with alpha
of 0.05 and 90% power. Allowing a 10% increase in sample to
account for variation in rates and 10% more for possible attrition,
it was decided to enroll 312 children per group.
Intervention
Fonterra Brands (Singapore) Pte. Ltd. provided fortified and
control milk powder packed into 32 g single serve sachets. During
enrollment into the study, mothers were explained the procedure
to reconstitute the milk powder before feeding. Both groups
received 21 sachets weekly at home by the Milk assistant (MA),
with an advice to consume three sachets a day. The intervention
was carried out for 1 year. Data on compliance and unused sachets
were collected every week. Intervention (fortified milk per 3 serves
a day) was designed to deliver 2.4 g of prebiotic oligosaccharide
and 1.9610
7 c.f.u of probiotic Bifidobacterium lactis HN019.
Oligosaccharide acted as a substrate, to facilitate the growth and
activity of Bifidobacterium lactis HN019 in the gastrointestinal tract.
The composition of milk in PP and Co group is given in Table 1.
Irrespective of group allocation, all children with severe anemia at
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addition to their milk supplement.
Follow up Observation
A team of Morbidity supervisors (MS) undertook twice weekly
home visits to collect prospective follow up morbidity information.
Information on compliance to intervention was collected by both
Milk (MA) and Morbidity (MS) teams. Before the start of the trial,
we organized workshops to train and establish reliability among
the field team members for measuring respiratory rate (RR),
temperature and lower chest in drawing. Reliability exercises were
repeated at scheduled intervals. At each home visit, morbidity
information for each of the previous 3–4 days since last visit was
recorded, including number of diarrheal stools, consistency of
stools and blood in stools, pneumonia, fever, ear discharge,
measles, vomiting and feeding history. During these biweekly
visits, MS team measured RR and temperature of the child, and
looked for signs of lower chest in-drawing. Whenever any of these
parameters was found to be more than the normal range, children
were referred to study physician for further examination.
Household was revisited by MS/MA on the next day, in case the
child or the parent was not available on a scheduled visit day. Two
levels of supervision and random checking were established above
the MA and MS level to ensure quality control of data. Mothers
were advised to contact study physicians at the clinic if they felt that
the child was sick between visits. Treatment of diarrhea, dysentery
and pneumonia as per WHO guidelines was provided free to the
participating children throughout the study. All visits either to the
study physicians or to private physicians were recorded.
The anthropometric measurements were repeated after 6
months and one year of intervention. The blood sampling was
repeated after one year of supplementation.
Definitions of Outcomes
Primary outcomes were not explicitly prespecified in the
protocol; the intent was to evaluate impact on common childhood
illnesses including diarrhea, pneumonia, and febrile illness.
However, the sample size was estimated based upon the effects
on diarrhea and pneumonia.
Diarrhea was defined as $3 loose or watery stools in 24 hours,
and diarrheal episodes were considered recovered on first day of
three diarrhea free days. Dysentery was defined as diarrhea with
visible blood in stools. We used field based pneumonia definition
[26]. Severe ALRI was defined as RR.=50/min, Pneumonia
was defined if a) severe ALRI was present or b) RR was.=40/
min but was accompanied by either lower chest in-drawing or
temperature of .=37.7uC.
Axillary temperature of $38.4uC was considered as high fever.
Severe illness was defined as days with temperature $38.4uCo r
hospitalization or RR$50/min or chest in-drawing associated
with it.
Data Management and Statistical Analysis
The data collected in the field on a pre-designed data collection
form was entered, collated and stored in the relational database
management system developed in Oracle 8i with stringent range,
consistency and logical checks. Real time data entry, data being
entered by the end of next day after data collection, ensured data
quality and accuracy. A double data entry and manual checking of
frequencies was performed during data cleaning. We performed
intent to treat analysis, i.e. all children were included in analyses
irrespective of supplement adherence. For children out-migrating
or withdrawing from the study, data were included until the date
of censorship. Person-time analysis was performed with actual
follow-up as denominator. For the effect on incidence (diarrhea,
ALRI, dysentery, measles), relative risk has been estimated using
Poisson regression and for prevalence, odds ratio has been
estimated using General Linear Model for binomial outcomes
(maximum likelihood logit estimation for grouped data). Both
estimations were performed in STATA 9.2, (Stata Corp, Union
Station, TX, USA), and SPSS ver. 12.0 (SPSS Inc., NJ, USA).
Anthropometric Z scores were calculated using WHO standards
[27].
Results
Out of 651 eligible children contacted, 624 children [312 in
intervention (prebiotic and probiotic milk (PP), 312 in control milk
(Co)] were enrolled into the trial (Figure 1). At enrollment,
children allocated to the groups were comparable for socio
economic, demographic descriptors, hematology and nutritional
status (Table 2). At baseline, 55% of children in both the groups
were partially breastfed. The adherence to study milk feeds was
high and similar in both groups, 84.0% children in the PP group
and 82.7% in Co group consumed two or three servings on .80%
days. This did not vary by the intervention period. No adverse
event because of intervention was observed during the course of
the study. Of the total follow up period, information was not
available for 19% of the child-days in the prebiotic and probiotic
group and 21% of the child days in the control group due to non-
availability of the children and their parents. Six children in the
prebiotic and probiotic group and five children in the control
group had withdrawn consent during the follow up.
Table 1. Composition of prebiotic and probiotic fortified milk
and control milk.
Nutritive Value (per day)
Prebiotic & Probiotic
fortified Milk (PP)
Control
milk (CO)
Energy (kJ) 1890 1890
Protein (g) 20.1 20.1
Carbohydrates (g) 50.1 50.1
Fat (g) 19.2 19.2
Vitamin A
a (mg) 300 300
Vitamin D (mg) 5.1 5.1
Vitamin E
b (mg) 6 6
Vitamin C (mg) 48 48
Folate DFE
c (mg) 114 114
Vitamin B 12(mg) 2.7 2.7
Calcium (mg) 720 720
Phosphorous (mg) 540 540
Iron (mg) 5.4 5.4
Zinc (mg) 3.3 3.3
Prebiotic-oligosaccharides (g) 2.4 0
Bifidobacterium lactis HNO19 (cfu)
d 1.9610
7 0
aRetinol activity equivalents.
ba-tocopherol equivalents.
cDietary Folate Equivalents.
dColony forming unit.
Milk Ingredients: Skim milk, Corn syrup solids, Cream, Sucrose, Vegetable oils
(soya and sunflower), Lactose, Fish oil, Lecithin, Vanillin, Vitamins: Vitamin A,
Vitamin D3, Vitamin E, Thiamin hydrochloride, Pyridoxine hydrochloride,
Vitamin C, Folate, Niacinamide, Minerals: Ferrous sulphate, Zinc sulphate
(Fortified milk contains additional prebiotic and Bifidobacterium lactis HNO19).
doi:10.1371/journal.pone.0012164.t001
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(95% CI: 21 to 12%; p=0.08) compared to children in Co group.
Ancillary analysis based on age revealed a significant age
interaction, therefore making overall rate reduction less meaning-
ful; for children aged 12 to 24 months rate of diarrhea was [1%
lower (95% CI: 211% to 11%), p=0.91] and children aged .24
months it was [10% lower (95% CI: 2% to 17%), p=0.02]; p-
value for test of difference=0.03. The incidence of dysentery was
Figure 1. Schematic representation of trial design.
doi:10.1371/journal.pone.0012164.g001
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probiotic group than the control group (Table 3).
There was a 24% reduction (95% CI: 0 to 42%) in incidence of
pneumonia (field based definition) and 35% reduction (95% CI: 0
to 58%) in severe ALRI in the prebiotic and probiotic fortified
group compared to the control group. Although statistically
significant, the confidence interval of this difference was wide and
compatible with small or no difference at upper bound of
confidence interval (Table 3).
The prevalence of severe illness among children consuming
prebiotic and prebiotics-fortified milk was 16% (95% CI: 5 to
26%; p=0.004) lower than the control group. This was similar
among children 1 to 2 years [20% lower (95% CI: 1 to 35%);
p=0.05], and 2 to 4 years [15% lower (95% CI: 2 to 27%);
p=0.03] (Table 3). Children in the prebiotic and probiotic
fortified group showed a statistically significant 5% fewer days with
high fever and 7% lower prevalence of ear discharge compared to
control group. The antibiotics usage was [6% (95% CI: 3 to 9%),
p,0.001] less among children consuming fortified milk (Table 3).
Sub group analyses based on breast-feeding, malnutrition and
anemia have been presented in supplementary tables (see Tables
S1, S2, S3, S4, S5 and S6).
Discussion
This study, reports the first large randomized controlled trial,
evaluating effect of providing combination of prebiotic and
probiotic in milk for one year on both gut and non-gut related
illnesses among children in a community based setting. We found
a significant beneficial effect on dysentery, pneumonia and febrile
illnesses. Effect on diarrhea was restricted to children aged .24
months. Although age interaction was statistically robust, given the
exploratory nature of this finding, results need to be interpreted
with caution.
Health effects of probiotics can vary by the specific probiotic
used. Bifidobacterium lactis HN019 used in this study has shown
extensive safety and immune-stimulant activity in animal models
including impact in animal models for E.coli and rotavirus [28–30].
Immune-stimulant activity among healthy adult volunteers, with
no notable adverse health events has been documented [31–33].
Both intervention and control group children consumed similar
quantity of milk, and milk in both groups was iso-energic, with
identical macronutrient quality and quantity as well as quantity of
vitamins and minerals. The only difference was the milk for
children allocated to the prebiotic and probiotic group delivered
additionally 2.4 g/day of prebiotic oligosaccharide and 1.9610
7
c.f.u/day of probiotic Bifidobacterium lactis HN019. The results in
this study need to be interpreted as the effects of the combination
of oligosaccharide and Bifidobacterium lactis HN019. In addition, in
the interpretation of results we need to consider that the base milk
used was fortified with iron, zinc and vitamins and improved in
nutrient composition (Table 1). Although unlikely but, we cannot
exclude the possibility that this is important for success of
intervention and therefore effects observed may not be same if
prebiotic and probiotic were added to regular unfortified milk.
Enrolled children were randomly allocated to the two
intervention groups, and the participants, health workers and
investigators were masked to group allocation. The similar pattern
of compliance between intervention and control groups further
supports the belief that masking was very good. As the study relied
on active, biweekly follow up by household based surveillance, this
would have identified the occurrence of almost all the clinical
outcomes of interest, thereby further limiting the possibility of a
reporting bias.
Although there is substantial evidence for the role of probiotics
in diarrhea, majority of that evidence is either from treatment of
acute diarrhea [7,9,10,12], persistent diarrhea [13] or antibiotic
associated diarrhea [14–16] and occurrence of nosocomial
infections [34–36]. This evidence cannot be extrapolated to
prevention of diarrhea in healthy children. The overall reduction
in incidence of diarrhea of 6% in this study is similar to, the only
other large community based trial, conducted among Peruvian
infants and young children [23]. The results of a significant
reduction in dysentery episodes, and diarrheal episodes in children
2–4 years is consistent with results from other published
randomized controlled trials evaluating prevention of acute
diarrhea acquired in day care centers [20,37–41]. The significant
differential effect of probiotic on the incidence of diarrhea among
Table 2. Baseline characteristics of prebiotic and probiotic
fortified and control milk groups.
PP Group
(n=312)
Co Group
(n=312)
Age (mo)
a 22.266.4 22.966.8
(21.7)
b (21.6)
Age (#24 months)
c 191 (61.2) 191 (60.9)
Illiterate father
c 43 (13.8) 54 (17.3)
Illiterate mother
c 152 (48.7) 155 (49.7)
Occupation father
Daily wage labor
c 105 (33.7) 112 (35.9)
Occupation mother
Housewives
c 299 (95.8) 301 (96.5)
Socio economic status score
a 7.6662.57 7.1062.45
Water supply
Tap water
c 189 (60.6) 195 (62.5)
Hematological Status
Hemoglobin
a,d (g/L) 91.1615.6 91.0614.9
93.0 (61.0;114.0)
e 92.0 (63.0; 114.0)
Zinc protoporphyrin
a,d
(mmol/mole heme)
193.466125.65 199.126124.99
151.5 (42.0; 481.7)
e 167 (55.8; 456.6)
Serum transferrin
a,d (g/L) 15.2568.85 15.2168.79
12.97 (5.68; 35.70)
e 13.22 (5.22; 35.49)
Serum ferritin
a,d (mg/L) 9.2367.96 9.8769.09
6.81 (2.29; 25.7)
e 6.75 (2.15;29.76)
Redcell distribution width
a,d (%) 19.3662.75 19.3562.68
19.1 (15.1; 24.1)
e 19.3 (14.9; 23.8)
Iron deficient anemic
c 158 (54.1) 168 (56.9)
Nutritional status
Normal
c 107 (34.3) 95 (30.4)
Wasted and Stunted
c 53 (17.0) 46 (14.7)
Wasted
c 15 (4.8) 14 (4.5)
Stunted
c 137 (43.9) 157(50.3)
aMean6SD.
bMedian age.
cNumber (%).
dReference values for hematological markers: Hb.100 g/L, Zinc Protoporphyrin
,80 mmol per mole of heme, serum Transferrin #8.3 mg/ml, serum Ferritin
.12mg/L, Red Cell Distribution Width #14%.
eMedian (5
th;9 5
th percentile).
doi:10.1371/journal.pone.0012164.t002
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the previous studies. The lack of effect in children below 24
months of age could be due to one or more of the following:
a) difference in the constitution of the gut flora among children
.24 months of age, b) a shift in Th1 and Th2 balance. During
infancy, the cellular immune system is maturing with a shift from
Th2 predomination at birth to Th1 predomination by second year
of life. The effect of probiotic may be limited in infants due to
intrinsic limitations in the capacity of infants to produce interferon
and other Th1 interleukins (IL-2, IL12), c) Breastfeeding among
younger children may have modified the effect of probiotic, as
studies have suggested greater benefits of prebiotic and probiotic in
non-breastfed children as compared to breast fed children [23].
We did not observe significant difference in diarrhea reduction
between breast fed and non breast fed children in the age group of
12–24 months; however given lack of power we also cannot
exclude it.
Although we did not evaluate etiology of diarrhea in this study,
previous evaluation have shown rotavirus to be responsible for
2.3% of cases, enterotoxigenic Escherichia coli and enteropathogenic
Escherichia coli as major causes with 13.5% and 6.3% of cases,
while for dysentery Salmonella species and Shigella species account for
3.2 and 1.8% of cases [42]. Cholera is not endemic in this
population.
A reduction in incidence and prevalence of febrile illness,
pneumonia, severe ALRI, marginal reduction in ear infections and
requirement for antibiotics is consistent with findings from the only
three studies which have evaluated prevention of similar morbidity
syndromes in healthy children [18–20]. However, these studies, for
many of these outcomes documented trends only, due to lack of
statistical power. This study which is the largest reported thus far,
implemented an active home based surveillance for morbidity and
had a follow up of full one year which potentially provided
sensitive estimation of the morbidity. The beneficial effects
documented in this study are multi-systemic, indicating that the
underlying mechanism for the beneficial effects most likely was
due to improved immune response to viral and bacterial infections.
Improvement in immunity could have been mediated through
improved production of antimicrobial substances, attachment in
intestinal mucosal sites, inhibition of the attachment and growth of
pathogenic organisms by achieving competitive exclusion and
microbial balance leading to regeneration of gut epithelium and
consequently resulting in better absorption of nutrients [43–46].
However given the variation in effects of probiotics upon such
immune mechanisms, the observed effects should be interpreted as
effects of the preparation used in this study and not generalized to
all prebiotic and probiotic combinations.
Reducing the preventable childhood illnesses among preschool
children in developing countries is an important public health
goal, that would not only impact mortality by breaking
malnutrition cycle but would also impact better development of
children. The findings of this study suggest that fortification with
prebiotic and probiotic together may provide one of the potential
interventions to reduce the burden of common childhood
morbidities. However, before any public health recommendations
are made, these results need to be confirmed in varied settings and
with locally available probiotic strains.
Supporting Information
Table S1 Episodes of common childhood morbidities for
children who were breast fed.
Table 3. Effect of prebiotic oligosaccharide and probiotic Bifidobacterium lactis HN019 fortified milk on common childhood
morbidities.
PP group (n=312) Co group (n=312)
Odds Ratio
(95% CI) p value
Actual
numbers
Episodes per
child year
Actual
numbers
Episodes
per child year
Gastrointestinal morbidity
Diarrhea episodes (1–4 y) 1641
a 6.21
b 1697
a 6.61
b 0.94 (0.88–1.01) 0.08
#24 mo 603 2.3 563 2.2 0.99 (0.89–1.11) 0.91
.24 mo 1038 3.92 1134 4.41 0.90 (0.83–0.98) 0.02
Dysentery episodes 125 0.47 154 0.6 0.79 (0.62–1.00) 0.05
Respiratory morbidity
Pneumonia episodes
c 90 0.34 115 0.45 0.76 (0.58–1.00) 0.05
Severe ALRI episodes
d 34 0.13 51 0.20 0.65 (0.42–1.00) 0.05
Febrile illness and others
Days with severe illness (1–4 y) 473 1.8 550 2.14 0.84 (0.74–0.95) 0.004
#24 mo 153 0.58 177 0.69 0.80 (0.65–0.99) 0.05
.24 mo 320 1.21 373 1.5 0.85 (0.73–0.98) 0.03
Days with ear discharge 1550 5.87 1613 6.3 0.93 (0.87–1.00) 0.06
Days with high fever 2798 10.6 2865 11.2 0.95 (0.90–1.00) 0.05
Measles 5 0.02 10 0.04 0.49 (0.17–1.42) 0.19
Doses of antibiotics consumed 7402 28.02 7625 29.7 0.94 (0.91–0.97) ,0.001
aActual numbers.
bEpisodes per child year.
cField based Pneumonia Definition a) If RR was .=50/min, or b) RR was .=40/min but was accompanied by lower chest in-drawing or temperature of $37.7uC.
dRR.=50/min.
doi:10.1371/journal.pone.0012164.t003
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DOC)
Table S2 Episodes of common childhood morbidities for
children who were non breast fed.
Found at: doi:10.1371/journal.pone.0012164.s002 (0.04 MB
DOC)
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